Clinical data | |
---|---|
Other names | 18-Methylmetribolone; 17α-Methyltetrahydrogestrinone; 17α-Methyl-THG; ∆9,11-17α,18-dimethyl-19-nortestosterone; 17α,18-Dimethylestr-4,9,11-trien-17β-ol-3-one |
Drug class | Androgen; Anabolic steroid |
Identifiers | |
| |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C20H26O2 |
Molar mass | 298.426 g·mol−1 |
3D model (JSmol) | |
| |
|
RU-2309, also known as 18-methylmetribolone, δ9,11-17α,18-dimethyl-19-nortestosterone, or 17α,18-dimethylestr-4,9,11-trien-17β-ol-3-one, is a 17α-alkylated androgen/anabolic steroid (AAS) of the 19-nortestosterone group which was never marketed.[1][2][3] It is the C18 methyl or C13β ethyl derivative of metribolone.[1][2] The compound is closely related to tetrahydrogestrinone (THG), which has the same chemical structure as RU-2309 except for possessing an ethyl group at the C17α position instead of a methyl group.[4] Hence, it could also be referred to as 17α-methyl-THG.[4] RU-2309 shows high affinity for the androgen, progesterone, and glucocorticoid receptors.[1][2][3]